Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with stage II-IIIA NSCLC
Lung Diseases|Neoplasms|Respiratory Tract Diseases|Thoracic Neoplasms|Non-small-cell Lung Cancer
DRUG: Sintilimab injection
Major pathologic response rate(MPR)(<10% viable tumor cells), To assess the major pathologic response rate (\<10% viable tumor cells) in patients receiving Sintilimab Injection, At time of surgery
Disease Control Rate (DCR), the proportion of patients with a best overall response of CR, PR or SD in the whole body, as assessed per RECIST 1.1 by the investigator., up to 2 years|Overall response rate (ORR), the proportion of patients with a best overall confirmed response of CR or PR in the whole body as assessed per RECIST 1.1 by the investigator, up to 2 years|Disease-free survival (DFS), Defined as the time from date of surgery until recurrence of tumor or death from any cause, up to 2 years|Incidence of irAEs, Immune-related AE per Common Terminology Criteria for Adverse Events (CTCAE V5.0), up to 2 years|Incidence of SAEs, Grade 3 or higher per Common Terminology Criteria for Adverse Events (CTCAE V5.0), up to 2 years
Sintilimab injection (IBI308) as neoadjuvant therapy in patients with resectable NSCLC